Opaleye Management as of Dec. 31, 2023
Portfolio Holdings for Opaleye Management
Opaleye Management holds 46 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Harrow Health (HROW) | 11.5 | $43M | 3.8M | 11.20 | |
| Tg Therapeutics (TGTX) | 10.1 | $38M | 2.2M | 17.08 | |
| Acelyrin (SLRN) | 8.3 | $31M | 4.1M | 7.46 | |
| Rhythm Pharmaceuticals (RYTM) | 7.5 | $28M | 610k | 45.97 | |
| Ocular Therapeutix (OCUL) | 7.3 | $27M | 6.1M | 4.46 | |
| Catalyst Pharmaceutical Partners (CPRX) | 5.7 | $21M | 1.3M | 17.05 | |
| Keros Therapeutics (KROS) | 3.8 | $14M | 358k | 39.76 | |
| Ideaya Biosciences (IDYA) | 3.0 | $11M | 312k | 35.58 | |
| Eton Pharmaceuticals (ETON) | 3.0 | $11M | 2.5M | 4.38 | |
| Crinetics Pharmaceuticals In (CRNX) | 2.9 | $11M | 308k | 35.58 | |
| Arvinas Ord (ARVN) | 2.9 | $11M | 264k | 41.16 | |
| Codexis (CDXS) | 2.5 | $9.3M | 3.0M | 3.05 | |
| Biohaven (BHVN) | 2.3 | $8.6M | 200k | 42.80 | |
| Edgewise Therapeutics (EWTX) | 2.0 | $7.6M | 699k | 10.94 | |
| Iovance Biotherapeutics (IOVA) | 2.0 | $7.3M | 897k | 8.13 | |
| Arcutis Biotherapeutics (ARQT) | 1.7 | $6.3M | 2.0M | 3.23 | |
| 4d Molecular Therapeutics In (FDMT) | 1.7 | $6.3M | 309k | 20.26 | |
| Marinus Pharmaceuticals Com New (MRNS) | 1.6 | $6.1M | 564k | 10.87 | |
| Vaxcyte (PCVX) | 1.5 | $5.7M | 90k | 62.80 | |
| Liquidia Corporation Com New (LQDA) | 1.4 | $5.4M | 445k | 12.03 | |
| Protara Therapeutics Com Stk (TARA) | 1.4 | $5.0M | 2.7M | 1.88 | |
| Urogen Pharma (URGN) | 1.3 | $4.8M | 320k | 15.00 | |
| Xoma Corp Del Com New (XOMA) | 1.2 | $4.6M | 250k | 18.50 | |
| Applied Therapeutics (APLT) | 1.0 | $3.7M | 1.1M | 3.35 | |
| Relmada Therapeutics (RLMD) | 1.0 | $3.6M | 877k | 4.14 | |
| Trevi Therapeutics (TRVI) | 0.9 | $3.4M | 2.5M | 1.34 | |
| Jasper Therapeutics | 0.8 | $3.1M | 4.0M | 0.79 | |
| Intellia Therapeutics (NTLA) | 0.8 | $3.0M | 99k | 30.49 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.8 | $3.0M | 265k | 11.17 | |
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.8 | $2.9M | 8.0M | 0.36 | |
| Larimar Therapeutics (LRMR) | 0.8 | $2.8M | 624k | 4.55 | |
| Ventyx Biosciences (VTYX) | 0.8 | $2.8M | 1.1M | 2.47 | |
| Syros Pharmaceuticals Com New (SYRS) | 0.7 | $2.8M | 359k | 7.79 | |
| Gossamer Bio (GOSS) | 0.7 | $2.7M | 3.0M | 0.91 | |
| Protagonist Therapeutics (PTGX) | 0.7 | $2.6M | 113k | 22.93 | |
| Kalvista Pharmaceuticals (KALV) | 0.5 | $1.8M | 150k | 12.25 | |
| Verastem Com New (VSTM) | 0.5 | $1.7M | 211k | 8.14 | |
| Nyxoah S A SHS (NYXH) | 0.4 | $1.6M | 345k | 4.64 | |
| Morphosys Sponsored Ads (MOR) | 0.4 | $1.4M | 145k | 9.90 | |
| Precigen (PGEN) | 0.4 | $1.4M | 1.0M | 1.34 | |
| Sutro Biopharma (STRO) | 0.3 | $1.3M | 302k | 4.29 | |
| Context Therapeutics (CNTX) | 0.3 | $1.1M | 975k | 1.13 | |
| Biodesix (BDSX) | 0.2 | $914k | 497k | 1.84 | |
| Fulcrum Therapeutics (FULC) | 0.2 | $878k | 130k | 6.75 | |
| Aligos Therapeutics | 0.2 | $861k | 1.3M | 0.66 | |
| Kiniksa Pharmaceuticals Com Class A | 0.2 | $640k | 38k | 17.07 |
